GLP-1RAs were associated with lower risk for major adverse cardiovascular and cerebrovascular events in MGUS with type 2 diabetes.

A study has found that greater cancer risk is associated with worse cardiovascular health metrics and cardiovascular disease risk scores.

Pemivibart was well tolerated and prophylactic against COVID-19 infection among adult patients with significant immunocompromising conditions.